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Abstract
Mutations in the FOXA1 transcription factor define a unique subset of prostate cancers but the 
functional consequences of these mutations and whether they confer gain or loss of function is 
unknown1-9. By annotating the FOXA1 mutation landscape from 3086 human prostate cancers, we 
define two hotspots in the forkhead domain: Wing2 (~50% of all mutations) and R219 (~5%), a 
highly conserved DNA contact residue. Clinically, Wing2 mutations are seen in adenocarcinomas 
at all stages, whereas R219 mutations are enriched in metastatic tumors with neuroendocrine 
histology. Interrogation of the biologic properties of FOXA1WT and 14 FOXA1 mutants revealed 
gain-of-function in mouse prostate organoid proliferation assays. 12 of these mutants, as well as 
FOXA1WT, promoted an exaggerated pro-luminal differentiation program whereas two different 
R219 mutants blocked luminal differentiation and activate a mesenchymal and neuroendocrine 
transcriptional program. ATAC-seq of FOXA1WT and representative Wing2 and R219 mutants 
revealed dramatic, mutant-specific changes in open chromatin at thousands of genomic loci, 
together with novel sites of FOXA1 binding and associated increases in gene expression. Of note, 
peaks in R219 mutant expressing cells lack the canonical core FOXA1 binding motifs 
(GTAAAC/T) but are enriched for a related, non-canonical motif (GTAAAG/A), which is 
preferentially activated by R219 mutant FOXA1 in reporter assays. Thus, FOXA1 mutations alter 
its normal pioneering function through perturbation of normal luminal epithelial differentiation 
programs, providing further support to the role of lineage plasticity in cancer progression.
To investigate the role of mutant and wild-type FOXA1 in prostate cancer, we examined the 
landscape of FOXA1 alterations across a cohort of 3086 patients with primary or metastatic 
disease. The overall frequency of FOXA1 alteration is ~11% (Fig. 1a, b), 3% of which are 
genomic amplifications and 8.4% somatic point mutations, with <1% having both (Fig. 1b). 
Over 50% of FOXA1 mutations map to a specific hotspot in Wing2 of the forkhead (FKHD) 
DNA-binding domain, often as missense or indels in Wing2 (mainly between H247 and 
F266), some of which are predicted direct DNA contact sites10 (Fig. 1a, Extended Data Fig. 
1). R219 is a DNA contact site in α-helix 3, a highly conserved fold of the FKHD domain 
that sits in the major groove of target DNA (Extended Data Fig. 1). Finally, 20% encode 
truncation mutations just downstream of the FKHD DNA-binding domain, resulting in loss 
of the C-terminal transactivating domain. Annotation of all FOXA1 mutations in the MSK-
IMPACT 504 cohort11 revealed that Wing2 hotspot mutations, the most common subclass, 
are found across all disease stages but more prevalent in primary locoregional cases (Fig. 
1c). There are only 4 cases of FOXA1R219 mutation in this cohort but, intriguingly, 2 had 
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castration resistant disease. We therefore expanded the analysis to 1822 patients by 
including a larger cohort from MSK-IMPACT and a published cohort from Weill-Cornell 
enriched for neuroendocrine prostate cancer (NEPC)12 and observed significant enrichment 
(p<0.006) of FOXA1R219 mutation versus other FOXA1 mutations in NEPC (3 out of 4) 
versus adenocarcinoma (8 out of 84) (Fig. 1d).
We next asked if FOXA1 mutation in patients is associated with clinical outcome. In the 
absence of appropriate longitudinal data, we generated an RNA signature using mutant 
FOXA1 status of TCGA samples to query the Decipher GRID cohort of 1626 primary 
prostate cancer patients13 and found that tumors predicted to be FOXA1 mutant were 
significantly associated with higher Gleason Scores, shorter time to biochemical recurrence, 
and more rapid progression to metastatic disease than unaltered cases (Extended Data Fig. 
1b,c). Together with recent evidence14, these data suggest that patients with FOXA1 
mutations have less favorable prognosis.
To characterize a large panel of the most recurrent alterations seen in prostate cancer, 
including truncating mutations (G275X), we generated a novel FOXA1 reporter construct 
(Extended Data Fig. 2), and found that all Wing2 mutations, D226N (a mutation in 3D 
proximity to Wing210) and the truncation mutant G275X have increased transcriptional 
activity (~2 fold) compared to wild-type, whereas mutations at R219 (R219S and R219C) 
showed impaired activity (~50% of WT) (Fig. 2a). To explore the consequences of FOXA1 
mutations on growth of prostate cells, we utilized primary mouse prostate organoid culture 
(previously used to model tumor initiation)15 by introducing a series of wild-type or mutant 
mouse Foxa1 alleles using doxycycline (dox)-inducible lentiviral constructs (Extended Data 
Fig. 3a-c). Increased expression of FOXA1WT resulted in a 2–3 fold increase in growth 
compared to vector control (EV). This relative difference was substantially greater (~50-
fold) after removal of epidermal growth factor (EGF), a critical growth factor for normal 
organoid proliferation (Fig. 2b). In this setting, nearly all mutants tested led to an increase in 
growth compared to overexpression of FOXA1WT, including the two helix 3 mutants 
(R219S and R219C) that had reduced reporter activity, as well as the truncation mutant 
G275X (Fig. 2c). All 14 promoted growth relative to the EV control line.
We next examined the histological features of these organoids. Strikingly, we observed that 
increased expression of FOXA1WT, FOXA1D226N and the Wing2 hotspot mutations all 
promote exaggerated lumen formation and size (Fig. 2d-e, Extended Data Fig. 3d). In 
contrast, organoids expressing FOXA1R219S, and to a lesser extent those expressing 
FOXA1R219C, were unable to form measurable lumens and the bi-layer orientation of basal 
(p63+) and luminal (AR+) cell layers appeared disrupted (Fig. 2e, Extended Data Fig. 3e). 
This phenotype resembles that of FOXA1-deficient organoids generated using CRISPR/
Cas9 (Extended Data Fig. 4a-c), consistent with mouse models16. We also repeated the 
overexpression studies in endogenous Foxa1-deleted organoids using CRISPR-resistant 
cDNAs encoding two pro-luminal mutants (FOXA1F254_E255del and FOXA1D226N) and 
found that the pro-luminal phenotype was unchanged (Extended Data Fig. 4d-g). Findings 
from RNA sequencing were consistent with these histologies. Mutants conferring a pro-
luminal phenotype showed similarity to ETS-mutant luminal organoids17 by gene set 
enrichment analysis with the notable exception being FOXA1R219S which instead showed 
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enrichment of an epithelial-mesenchymal-transition (EMT) program and a repression of the 
ETS mutant gene set (Fig. 2f), consistent with its distinct morphology. We also examined the 
activity of FOXA1 in an in vivo setting18,19 and saw increased proliferation across all lines, 
an increase in subcutaneous tumor size in 2 of 4 lines (FOXA1WT and FOXA1G275X), and 
an increased prevalence of invasive, intraductal basal disease (defined by the loss of AR 
expression) in tumors derived from sgPTEN+FOXA1R219S organoids, consistent with 
FOXA1R219S histology in vitro (Extended Data Fig. 4h-j).
Given that FOXA1 is a cofactor for AR and that FOXA1 mutant cases in the TCGA cohort 
have higher AR scores than either normal samples or other subtypes6, we examined the AR 
cistrome. Intriguingly, the number of AR binding peaks (defined by AR ChIP-seq) is 
markedly reduced in organoids overexpressing wild-type or mutant FOXA1 (Fig. 3a, left, 
Extended Data Fig. 6a). However, FOXA1 binding is enhanced at the sites where AR 
binding is lost (Fig. 3a, right, p<1e-300, Extended Data Fig. 5a). This result suggests that 
FOXA1 may replace AR function at these sites, supported by the fact that the increased 
growth advantage conferred by FOXA1 is retained despite CRISPR deletion of Ar (Fig. 3b, 
Extended Data Fig. 5b). To reconcile the high AR scores seen in TCGA with this AR-
independent growth program, we examined expression levels of the mouse orthologs of the 
human AR gene signature20 and found that the majority are induced by FOXA1 (Extended 
Data Fig. 5c). Thus, while the number of AR binding sites is substantially reduced, a core 
set of AR target genes are maintained in the setting of increased FOXA1 activity. We also 
asked if transcriptomic changes observed in the FOXA1-mutant mouse organoids were 
similar to those observed in FOXA1-mutant human tumors. Remarkably, the human 
orthologs of differentially expressed genes (DEGs) in FOXA1F254_E255del murine organoids 
were sufficient to cluster FOXA1 mutant tumors within the TCGA cohort (P = 2.1 × 10−8, 
Extended Data Fig. 5d).
Given the role of FOXA1 as a pioneering transcription factor, we conducted a genome wide 
analysis of changes in open and closed chromatin using Assay for Transposase Accessible 
Chromatin sequencing (ATAC-seq). FOXA1WT expression led to an increase in open 
chromatin after 5 days (>1000 open peaks with significant change in accessibility, FDR < 
0.05, log fold change of 2 in peak read coverage compared to control) whereas Foxa1 
deletion led to the opposite, with the closing of ~1000 peaks. Organoids expressing 
FOXA1F254_E255del and FOXA1R219S also had increased peak numbers, but these changes 
occurred substantially faster (1 day) and involved many more peaks (Fig. 4a), consistent 
with altered pioneering activity.
Unsupervised clustering analysis identified distinct sets of peaks for FOXA1F254_E255del and 
FOXA1R219S (Fig. 4b). Cluster 0 is largely defined by dramatic peak changes observed with 
both FOXA1WT and FOXA1F254_E255del, demonstrating that overexpression of wild-type 
FOXA1 opens new regions of chromatin compared to control, which are even further 
exaggerated in cells expressing FOXA1F254_E255del. In contrast, organoids expressing 
FOXA1R219S gain thousands of distinct peaks (defined by clusters 3 and 5) without changes 
in cluster 0. ChIP-seq reveals that FOXA1 protein is binding at these same ATAC-seq loci 
(Fig. 4c, Extended Data Fig. 6a-d) and CDF plots confirm mutant-specific changes in 
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expression of the genes that map to these newly open chromatin peaks (Extended Data Fig. 
6e-h).
Curiously, motif analysis revealed enrichment of FOXA binding motifs in clusters 0 and 1 
(FOXA1WT and FOXA1F254_E255del) (Extended Data Fig. 7a) but not in clusters 3 and 5 
(FOXA1R219S) despite evidence of FOXA1R219S DNA binding and associated gene 
expression changes. However, de novo motif analysis of cluster 3 peaks identified a motif 
with similarities to the core GTAAA(C/T) FOXA1 binding motif but with substitution of 
(G/A) at position 6 for (C/T) (Extended Data Fig. 7b). This impression was confirmed by 
selective enrichment of the (G/A) motif in clusters 3 and 5 versus the (C/T) motif in clusters 
0 and 1 (Fig. 4d). To provide evidence that this neomotif is functional, we repeated the 
reporter assays described previously (Fig. 2a) and found FOXA1R219S preferentially 
activates a DNA template modified to reflect the (G/A) bias at position 6, whereas 
FOXA1WT and FOXA1F245_E255del exhibit substantially higher activity on the canonical 
(C/T) sequence (Fig. 4e, Extended Data Fig. 7c-e), suggesting a mechanism by which 
FOXA1R219S selectively targets novel genomic loci. Finally, two motifs recently associated 
with FOXA1 dimers (convergent, divergent)21 were relatively enriched in cluster 0 versus 
cluster 1, potentially explaining the novel pioneering activity of FOXA1F254_E255del (Fig. 
4d).
Collectively our analysis of mutant FOXA1 alleles in prostate cancer revealed unanticipated 
and diverse consequences for its pioneering function. Wing2 mutants have a gain in 
pioneering activity that is substantially greater than that observed by overexpression of 
comparable levels of FOXA1WT, but both alterations affect nearly identical regions of the 
genome (cluster 0) that are distinguishable from endogenous Foxa1 sites (cluster 1) based on 
enrichment of FOXA1 dimer motifs. We postulate that the changes in gene expression 
associated with these novel open regions contribute to oncogenesis. In contrast, FOXA1R219 
mutants display pioneering function over distinct regions of the genome (clusters 3 and 5) 
enriched for a variant FOXA1 binding motif that, based on reporter assays, is permissive for 
FOXA1R219 binding despite mutation of the helix 3 consensus DNA binding residue. 
Further investigation of relative DNA binding affinities of these mutants for the different 
motifs, as well as the potential role of the Wing2 domain in this retained DNA binding 
(based on known DNA contacts through the minor groove) is warranted. In both classes of 
mutations, the biological consequence is lineage plasticity for pro- versus anti-luminal 
programs.
Methods
Pan-prostate mutation analysis
The 12 cohorts used for analysis (total of 3086 samples) included published data sets as well 
as unpublished data from MSK-IMPACT 1708 cohort (frozen 5–25-18), across all stages of 
prostate cancer (see Table S1). Samples were compiled and duplicate samples were pruned 
to generate a master list of 3086 prostate cancer cases, which were then stratified based on 
their FOXA1 alteration status and the class of mutation in the samples. Wing2 hotspot 
includes cases with mutations or indels between H247 and E269. Truncations after the 
FKHD domain were defined as any frameshift alteration distal to residue E269. Any 
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mutations that did not specifically fall into one of the distinct classes was called ‘other.’ 
Sample analysis was performed in part using the CBioPortal for Cancer Genomics22,23.
3D modeling
Three-dimensional representation of the FKHD domain of FOXA3 complexed with DNA 
was generated using PyMOL (PDB: 1VTN).
Constructs
To create pCW-FLAG-2A-dsRED (pCW-EV), sequences for p2A and DsRED were cloned 
in the pCW-Cas9 plasmid (Addgene Plasmid #50661) using in-fusion cloning (Takara Bio). 
To generate pCW-FLAG-mFoxa1-2A-dsRED (pCW-Foxa1), mouse Foxa1 cDNA was 
cloned into pCW-FLAG-2A-dsRED using in-fusion cloning (Takara Bio). All primers and 
sequences are listed in Supplementary Table 2. To generate the sgRNA vector CRISPR-Zeo, 
GFP from pLKO5.sgRNA.EFS.GFP (a gift from Benjamin Ebert, Addgene plasmid #57822) 
was excised with BamHI and MluI. The Zeo-resistance gene was removed from lenti 
sgRNA(MS2)_zeo backbone (a gift from Feng Zhang, Addgene plasmid #61427) using 
BsrGI and EcoRI. ZeoR was ligated into the pLKO5.sgRNA.EFS backbone in a four-way 
ligation using BamHI/BsrGI and EcoRI/MluI adaptors. To create LVX-UbC-EGFP-
Luc2_Hygro construct in order to be able to visualize injected cells by live imaging or GFP 
IHC, we first generated the plasmid LVX-UbC-EGFP-Luc2_Puro in the following way: 0.72 
kb EGFP cDNA from pQCXIP-EGFP24 was cloned into the BamHI and NotI sites of pLVX-
TRE3G-IRES (Clontech, cat. 631362) via a EcoRI/NotI cloning adaptor to make pLVX-
TRE3G-EGFP-IRES. The TRE3G promoter was then removed with an XhoI and BamHI 
digestion, and replaced with the 1.26 kb UbC promoter obtained from Duet011 (Addgene) 
with a PacI and BamHI digest and using a XhoI/PacI cloning adaptor to make pLVX-UbC-
EGFP-IRES. pLVX-UbC-EGFP-Luc2 was then constructed by cloning the 1.7 kb Luc2 
cDNA derived from pGL4.10(luc2) (Promega) with a HindIII and XbaI digest into the MluI 
and EcoRI sites of pLVX-UbC-EGFP-IRES via MluI/HindIII and XbaI/EcoRI cloning 
adaptors. The puromycin cassette was replaced with the hygromycin to generate LVX-UbC-
EGFP-Luc2_Hygro.
Generation of FOXA1 mutant cDNA
Site directed mutagenesis was carried out on pCW-FLAG-Foxa1–2A-dsRED to induce 
patient mutations in the cDNA using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent), according to manufacturer’s protocol. Primers were designed using Agilent’s 
QuikChange Primer Design tool (https://www.genomics.agilent.com/
primerDesignProgram.jsp). To prevent CRISPR/Cas9 targeting by sgFOXA1_1 sgRNA 
mutagenesis was used to introduce three silent mutations in the sgRNA recognition sequence 
(see Extended Data Fig. 8A).
Guide RNA design
Guide RNAs targeting murine Foxa1, Ar, and Pten were generated using the CRISPR 
Design Tool (http://crispr.mit.edu). sgFoxa1_1 targets the cDNA near the 5’ end, while 
sg_Foxa14 and sgFoxa1_15 target the FKHD DNA-binding domain. Control guides sgNT 
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(targeting safe harbor locus AAVS125 and sgGFP were used. All guide RNAs were cloned 
into lentiCRISPRv2 (Addgene #52961), lentiGuide-Puro (Plasmid #52963) or CRISPR-Zeo 
using BsmbI digest, per Zhang lab protocol. For cells carrying CRISPR-Zeo or lentiGuide-
Puro, lentiCas9-Blast (a gift from Feng Zhang, Addgene plasmid #52962) was used as the 
Cas9 source.
FOXA1 luciferase reporter pGL-5xFBS-Luc
Oligonucleotide fragments containing 6 tandem FKHD consensus (canonical or non-
canonical) motifs with 5bps spacers (Table S2) were cloned into pGL4.28 luc2CP/minP/
hygro (Pomega) between HindIII and XhoI restriction sites. Oligonucleotide sequences were 
verified using Sanger sequencing. Canonical FOXA1 binding sites were based on the top 
binding motifs predicted based on ChIP-seq results in HepG2 cells26, while non-canonical 
was based on top hit of de novo motif analysis of ATAC-seq cluster 3 using HOMER 
(Extended Data Fig. 10). The pGL-5xFBS-Luc was transiently transfected using 
Lipofectamine 2000 (ThermoFisher) into lentiX293T cells (Clonetech) along with CMV-
Renilla (pRL-CMV Renilla, Promega) as an internal control. Response ratios are expressed 
relative to signal obtained for the positive control wells transfected 170ng of pCMV6-
mFOXA1mycDDK (Origene #MR225487), which was set to 1, and the negative control 
well receiving 170ng of ‘stuffer’ DNA (pCW-FLAG-2A-dsRED (pCW-EV), no exogenous 
FOXA1), which was set to 0. To test the response of these reporters to varying levels of 
FOXA1 introduced into the system, ratios of pCMV6-mFOXA1mycDDK and pCW-EV 
constructs were altered, keeping the total amount of DNA transfected into each well 
constant. In evaluating the relative response ratios (RRR) between FOXA1WT and various 
mutants, one concentration of cDNA (170ng/well) was used and RRR reflect activity of 
given variant on the reporter. Luminescence measurements were taken 24 hours after 
transfection. All results are means and standard deviations from experiments performed in at 
least replicates (see figure legends for details), and Firefly luciferase activity of individual 
wells were normalized against Renilla luciferase activity.
Organoid Lines
Blue Red Organoids (BRO line) was established as previously described15 from mice 
harboring Red Fluorescent Protein (RFP) driven by a composite human Keratin 18 promoter 
and a Cerulean Fluorescent Protein (CFP) driven by a bovine Keratin 5 promoter27. BROs 
were transduced with lentiCrispv2 carrying either sgNT or sgFoxa1_1 and selected using 
puromycin. BRO lines were maintained in standard mouse organoid media conditions15. 
K14–1 organoids were derived from mice harboring an actin-GFP fusion protein driven by a 
human Keratin14 promoter28. K14–1 organoids were transduced with the allelic series of 
pCW-Foxa1 wild-type or mutant constructs, as well as pCW-EV as a control. Bulk cells 
were selected using puromycin. K14–1 organoids were maintained in standard mouse 
organoid media conditions15, with 2.5ng/mL EGF supplementation. For rescue experiments 
of either Foxa1 deletion or Ar deletion, K14–1 organoids carrying pCW-Foxa1 constructs 
were subsequently transduced with lentiCas9-blast, bulk selected with blasticidin, and next 
transduced with either CRISRP-Zeo sgFoxa1_1 or sgNT, or sgAR and bulk selected with 
zeocin. Rosa26-Cas9-sgPTEN-luc2-pCW-FOXA1 organoids were derived from a 
homozygous Rosa26 Lox-stop-Lox Cas9 mouse (C67BL/6J background, Jackson 
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Laboratory # 026175) and transduced with adenoCRE-GFP in vitro to gain expression of 
Cas9. These cells were then transduced with lentiGuide-Puro-sgPten and bulk selected with 
puromycin, transduced with LVX-UbC-EGFP-Luc2_Hygro and bulk selected with 
hygromycin, then were transduced with the allelic series of pCW-Foxa1 wild-type or mutant 
constructs or pCW-ERG, as well as pCW-EV as a control, and sorted for dsRED expression 
to enrich for transduced cells.
Organoid Culture
Murine organoids were sorted, cultured in 3D and transduced with lentiviruses as described 
previously15,29. Organoids infected with pCW-EV, pCW-FOXA1, or LentiCrispV2 
constructs were selected with 2μg/ml puromycin for 5 days, 3–4 days post transduction, 
while those infected with CRISPR-Zeo were selected for 7 days with 30μg/mL, 3–4 days 
post transduction. Transduction with Lenti-Cas9-Blast was followed by 5 days of selection 
in 10μg/ml blasticidin. Preparation of 3D organoids for histology was carried out as 
previously described15. H&E staining and IHC was carried out by the MSKCC Molecular 
Cytology Core.
Growth Assays
Organoids were treated with doxycycline (dox) (500ng/mL) to induce expression of the 
FOXA1–2A-DsRED fusion then sorted 2 days later to enrich for DsRED+ cells. Cells were 
seeded at a density of 10cells/μl (2,000 cells/20μl dome, 3 domes per line per time point, 
each dome in a single 48-well plate well) and maintained on dox for the duration of the 
assay, refreshing media every 2–3 days. Y-27632 was supplemented for the first feeding at 
10 μM. To measure proliferation, matrigel domes were washed with PBS, and then 
resuspended in 100μl of PBS, and CellTiter-Glo 2.0 Assay was used, following 
manufactures instructions. Triplicate values for each time point were averaged, and all 
values on subsequent days were normalized to the day 1 reading. Experiments were repeated 
at least three independent times and each line was normalized to the EV control readings for 
a given replicate.
Lumen Formation Assays
Organoids treated with doxycycline (dox) (500ng/mL) to induce expression of the FOXA1–
2A-DsRED fusion. Dox treated cells were sorted 2 days later to enrich for DsRED+ cells. 
Sorted cells were seeded in matrigel at a density of 3 cells/μl (eight 25μl domes per) and 
maintained on dox for the duration of the assay, with the media refreshed every 2–3 days. 
Y-27632 was supplemented for the first feeding at 10μM. After 10 days, organoids were 
scored for the presence or absence of a visible lumen by bright field microscopy, and percent 
of the total number of organoids that possessed a lumen was determined based on examining 
~50 to 200 organoids in a typical experiment. In CRISPR organoid lines sorting was not 
performed for lumen formation assay. Instead cells were trypsinized to a single cell 
suspension, counted using trypan blue exclusion, and then seeded as described above. 
Experiments were repeated three independent times.
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Lumen Area Measurements
Organoids treated with doxycycline (dox) (500ng/mL) to induce expression of the FOXA1–
2A-DsRED fusion. Dox treated cells were sorted 2 days later to enrich for DsRED+ cells. 
Sorted cells were seeded in matrigel in dilution series of densities ranging from 32 cells/μl 
down to 4 cells/μl (5 domes per density per line) and maintained on dox for the duration of 
the assay, with the media refreshed every 2–3 days. Y-27632 was supplemented for the first 
feeding at 10 μM. After 10 days, the area of each visible lumen was measured using light 
microscopy and Nikon NIS elements software. In a typical experiment, ~30–50 organoids 
were measured.
Western Blot
Membranes were probed with antibodies directed against AR (1:1,000, ER179(2), Abcam), 
FOXA1 (1:1000, Ab2, Sigma), Cyclophilin B (1:1000, EPR12703(B), Abcam), FLAG 
(1:1000, M2, Sigma) or PTEN (1:1000, D4.3, Cell Signaling). Signal was visualized with 
secondary HRP conjugated antibodies and ECL.
Immunohistochemistry
Organoids and tumors were processed and stained as described previously15. The following 
antibodies were used for staining on murine organoids and organoid derived xenografts: 
HNF-3 alpha/FoxA1 Antibody (3B3NB) 5ug/mL (Novus Biologicals), AR (1:1,000, N-20, 
Santa Cruz), p63 (1:800, 4A4, Ventana). Stainings were visualized with bright vision 
(Dako), Ki67 (Abcam #ab15580 at 1ug/ml).
In vivo experiments
In vivo xenograft experiments were done by subcutaneous injection of 2 ×106 dissociated 
organoid cells (Rosa26-Cas9-sgPTEN-luc2-pCW-FOXA1 or ERG) resuspended in 100 μl of 
50% matrigel (BD Biosciences, San Jose, CA) and 50% growth media into the flanks of 5 8–
12 week old male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (#005557, The Jackson 
Laboratory, Bar Harbor, ME) to yield 10 tumors per group. As soon as palpable, tumor 
volume was measured weekly using the tumor measuring system Peira TM900 (Peira bvba, 
Belgium). Tumors were then harvested at given timepoints for histology using 4% 
paraformaldehyde. All animal experiments were performed in compliance with the 
guidelines of the Research Animal Resource Center of the Memorial Sloan Kettering Cancer 
Center. In accordance with our IACUC and our approved protocol, none of the mice 
exceeded the maximal tumor burden allowed (total for both sides) of 2000mm3.
RNA isolation and sequencing
RNA was extracted from organoids using an RNeasy Kit (Qiagen). Freshly sorted dsRED+ 
cells were seeded in triplicate per infected construct at the start of the assay, and moving 
forward, replicates were processed independently, collected at the appropriate time points. 
Library preparation and sequencing were performed by the New York Genome Center, 
where RNA-sequencing libraries were prepared using the TruSeq Stranded mRNA Library 
Preparation Kit in accordance with the manufacturer’s instructions. Briefly, 100ng of total 
RNA was used for purification and fragmentation of mRNA. Purified mRNA underwent first 
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and second strand cDNA synthesis. cDNA was then adenylated, ligated to Illumina 
sequencing adapters, and amplified by PCR (using 10 cycles). Final libraries were evaluated 
using fluorescent-based assays including PicoGreen (Life Technologies) or Qubit 
Fluorometer (Invitrogen) and Fragment Analyzer (Advanced Analytics) or BioAnalyzer 
(Agilent 2100), and were sequenced on an Illumina HiSeq2500 sequencer (v4 chemistry, v2 
chemistry for Rapid Run) using 2 × 50bp cycles. Reads were aligned to the mm10 mouse 
reference using STARaligner30 (v2.4.2a). Quantification of genes annotated in Gencode 
vM2 was performed using featureCounts (v1.4.3) and quantification of transcripts using 
Kalisto (doi:10.1038/nbt.3519). QC was collected with Picard (v1.83) and RSeQC31 (http://
broadinstitute.github.io/picard/). Normalization of feature counts was done using the 
DESeq2 package (doi:10.1101/002832).
Analysis of RNA-sequencing from mouse organoids and patient samples
The gene read count data of TCGA primary prostate cancer were downloaded by GDC tool. 
The mouse and human homologous genes were downloaded from Mouse Genome 
Informatics of The Jackson Laboratory (http://www.informatics.jax.org/homology.shtml). 
Differential expression analyses were performed using DESeq2 (https://bioconductor.org/
packages/release/bioc/html/DESeq2.html) based on the gene read count data. Multiple-
hypothesis testing was considered by using Benjamini-Hochberg (BH; FDR) correction. The 
statistical significance of the overlap between two groups of genes was tested using Fisher’s 
exact test. GSEA was performed using JAVA program (http://www.broadinstitute.org/gsea) 
and run in pre-ranked mode to identify enriched signatures. The GSEA plot, normalized 
enrichment score and FDR and q-values were derived from GSEA output. The following 
gene sets were used: Hallmark Gene Sets, Neuroendocrine High12, Basal low32, and shERF 
up17.
Prostate cancer tumor samples and microarray data
A total of 1,959 radical prostatectomy (RP) tumor expression profiles were used for training 
and testing. For training and testing, we utilized RNA-seq expression and DNA mutation 
data from The Cancer Genome Atlas (TCGA) prostate cancer project6 (n=333). For testing, 
the expression profiles of retrospective (n=1,626) were derived from the Decipher GRID 
registry (). The retrospective GRID cohort was pooled from seven published microarray 
studies: Cleveland Clinic33 (CCF), Erasmus MC34, Johns Hopkins35 (JHMI), Memorial 
Sloan Kettering36 (MSKCC), Mayo Clinic37,38 (Mayo I and Mayo II), and Thomas Jefferson 
University39 (TJU). Associated accession numbers are: GSE79957, GSE72291, GSE62667, 
GSE62116, GSE46691, GSE41408, and GSE21032. DNA and RNA from the TCGA cohort 
were extracted from fresh frozen RP tumor tissue, as previously described6. RNA from the 
GRID cohorts was extracted from routine formalin-fixed, paraffin embedded (FFPE) RP 
tumor tissues, amplified and hybridized to Human Exon 1.0 ST microarrays (Thermo-Fisher, 
Carlsbad, CA).
FOXA1 mutant transcriptional signature
By following the similar strategy as previously reported for SPOP mutants13, we developed 
the FOXA1 mutant transcriptional signature that includes 67 genes differentially expressed 
between FOXA1 mutant and wild-type samples from TCGA prostate cancer RNA-seq data. 
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The low-expressed genes (mean RSEM <1) were filtered before the analysis. Specifically, 
we identified significantly differentially expressed genes by comparing FOXA1 mutants 
within forkhead DNA-binding domain and wild-type cases as determined from DNA 
mutational analyses among TCGA samples lacking ETS family gene fusions (ERG, ETV1, 
ETV4 and FLI1), using Wilcoxon rank-sum test and controlled for false discovery using 
Benjamini-Hochberg adjustment (FDR ≤0.05).
SCaPT development based on FOXA1 mutant transcriptional signature and SVM model
To predict tumors in the FOXA1 mutant subclass in the absence of DNA sequencing data 
(i.e., microarray datasets), we developed the SCaPT (SubClass Predictor based on 
Transcriptional data) model based on support vector machine (SVM) model. Given a set of 
training data marked with two categories, SVM builds a model that assigns testing data into 
one category or the other, making it a non-probabilistic binary linear classifier. In our SCaPT 
model, the training data were defined as the transcriptional z-scores of FOXA1 mutant 
signature from TCGA cohort. The testing data would be the transcriptional z-scores from 
RNA-seq or microarray expression data of FOXA1 mutant signature.
Prostate cancer molecular subclass prediction by decision tree
In each individual study of retrospective and prospective GRID cohorts, FOXA1 mutant 
subclass was firstly predicted using the SCaPT model. Next, using a decision tree and 
previously developed microarray-based classifiers for the ERG+ and ETS+ subtypes, we 
classified the remaining cases in each cohort. Some cases with both predicted FOXA1 
mutant and ERG+/ETS+ status were classified as conflict subclass, and the rest without 
FOXA1 mutant calling and outlier expression were considered as ‘other’ subclass.
Statistical analysis of human data
Statistical analyses were performed in R v3.4.0 (R Foundation, Vienna, Austria). All 
statistical tests were two-sided with the significance level of p <0.05. Univariate logistic 
regression analyses were performed on the combined cohort to test the statistical association 
between FOXA1 mutant status and clinical variables, including age, race, preoperative PSA, 
Gleason score, lymph node invasion (LNI), surgical margin status (SMS), extracapsular 
extension (ECE), and seminal vesicle invasion (SVI). We evaluated the associations between 
FOXA1 mutant status and patient outcomes including biochemical recurrence (BCR), 
metastasis (MET) and prostate cancer specific mortality (PCSM), based on Kaplan-Meier 
analysis.
Assay for Transposase Accessible chromatin (ATAC) coupled with Next Generation 
Sequencing (NGS)
Freshly sorted cells carrying pCW constructs (dsRED+) were seeded in triplicate per 
infected construct at the start of the assay, and moving forward, replicates were processed 
independently, collected at the appropriate time points. CRISPR cell lines carried 
LentiCRISPRv2 with either the control guide (sgNT), guide 14 for FOXA1 (“sgFOXA1_1”) 
or guide 15 for FOXA1 (“sgFOXA1_2”). At time of collection, cells were trypsinzed, and 
50,000 cells (counted by using trypan blue exclusion) were processed for ATAC-sequencing 
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as follows. After a wash step in cold Cell Wash Buffer (CWB= 10 mM Tris-HCl pH 7.4, 10 
mM NaCl, 3 mM MgCl2), outer membranes were disrupted in lysis buffer (CWB + 0.1% 
NP40) for 2min on ice. Lysis reaction was stopped with the addition of 1ml of CWB. After a 
centrifugation step 1,500g for 10min, pelleted nuclei are kept for the next step. In a 50μl 
final volume, tagmentation was performed for 30min at 37C, using the kit Nextera DNA 
library prep kit (Illumina cat# FC-121–1030). After addition of SDS 0.2% final 
concentration, DNA is purified in AMPure XP beads (Beckman Coulter cat# A63881) using 
a ratio 2:1 (V/V) beads:tagmented DNA.Freshly eluted DNA was barcoded and amplified in 
110μl PCR volume (NEB Next Q5 Hot Start HiFi PCR, cat# M0543L) to generate library 
with the following PCR program: 65C, 5min, 98C, 30sec, (98C, 10sec – 65C, 30sec) 
*11cycles, 4C hold. Quality control of the libraries was performed with Bioanalyzer 2200 
(Agilent technologies, D1000 screentapes & reagents, cat# 5067–5582) to assess size range 
of amplified DNA fragments and with Quant-iT™ PicoGreen™ dsDNA Assay Kit 
(Thermofisher cat# P11496) to quantify the DNA fragments generated. ATAC Libraries were 
then pooled at equimolar concentration and were sequenced multiplexed on the Illumina 
HiSeq with 50bp paired-end.
ATAC data and preprocessing
ATAC-seq data preprocessing was performed as previously described Raw ATAC-seq reads 
were trimmed and filtered for quality using Trim Galore! v0.4.5 (http://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/) powered by CutAdapt v1.16 
(https://doi-org.proxy.library.cornell.edu/10.14806/ej.17.1.200) and FastQC v0.11.7 (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/). Paired end reads were aligned to the 
mm10 genome using Bowtie2 v2.3.4.1 in very sensitive local mode (-q –local –very-
sensitive-local –no-discordant –no-mixed –dovetail -I 10 X 20), and paired reads that 
mapped to different chromosomes or that mapped too far away were discarded. Unpaired 
reads, discordant reads, reads with mapQ < 20, or SAM flags 0×4 and 0×400, as well as 
reads marked as optical or PCR duplicates using picard MarkDuplicates v2.18.3-
SNAPSHOT and reads overlapping the ENCODE mm10 functional genomics regions 
blacklist (at mitra.stanford.edu/kundaje/akundaje/release/blacklists/mm10-mouse/
mm10.blacklist.bed.gz) were removed to improve the quality of the retained fragments. To 
correct for the fact that the Tn5 transposase binds as a dimer and inserts two adapters in the 
Tn5 tagmentation step, all positive-strand reads were shifted 4 bp downstream and all 
negative-strand reads were shifted 5bp upstream to center the reads on the transposase 
binding event.
Overall mapping statistics confirmed high quality ATAC-seq data, with a high alignment rate 
(over 76.8% in all samples) and high coverage (over 30M aligned read pairs per sample) 
across experiments (Supplementary Table 13). As an additional quality control metric, we 
confirmed that all ATAC-seq libraries displayed the expected insert size distribution 
computed from aligned read pairs, with nucleosome-free, mono-nucleosomal, and di-
nucleosomal modes (see Extended Data Fig. 8a for representative plots).
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ATAC peak calling, reproducibility analysis and atlas creation
We then pooled the shifted reads by sample and identified peaks using MACS2 with a 
threshold of FDR-corrected P < 0.01 using the Benjamini-Hochberg procedure for multiple 
hypothesis correction. As called peaks may be caused by noise in the assay and not reflect 
true chromatin accessibility, we calculated an irreproducible discovery rate (IDR) for all 
pairs of replicates across a cell type. Given two ranked lists of events from replicate 
experiments, in this case peak calls ranked by P value, IDR estimates a threshold at which 
events are no longer reproducible. Using this measure, we excluded peaks that were not 
reproducible (IDR < 0.005) in at least one pair of replicates for at least one cell type/time 
point.
Reproducible peaks from each cell type were combined to create a genome-wide atlas of 
accessible chromatin regions. Reproducible peaks from different samples were merged if 
they overlapped by more than 75%. This produced an atlas of ~182.8K reproducible peaks 
of median width 586 bp. The numbers of reproducible peaks per time point and organoid 
line are provided in Supplementary Table 14. Track diagrams at specific loci visually 
confirm that replicate ATAC-seq experiments show reproducible accessible sites (Extended 
Data Fig. 8b).
Assignment of ATAC-seq peaks to genes
The RefSeq transcript annotations of the mm10 mouse genome were used to define the 
genomic location of transcription units. For genes with multiple gene models, the longest 
transcription unit was used for the gene locus definition. ATAC-seq peaks located in the 
body of the transcription unit, together with the 2kb regions upstream of the TSS and 
downstream of the 3′ end, were assigned to the gene. If a peak was found in the overlap of 
the transcription units of two genes, one of the genes was chosen arbitrarily. Intergenic peaks 
were assigned to the gene with a TSS or 3′ end that was closest to the peak. In this way, 
each peak was unambiguously assigned to one gene. Peaks were annotated as promoter 
peaks if they were within 2kb of a transcription start site. Non-promoter peaks were 
annotated as intergenic, intronic or exonic according to the relevant RefSeq transcript 
annotation. The atlas-wide distribution of promoter/intergenic/exonic peak assignment was 
consistent with high-quality ATAC-seq data sets (Extended Data Fig. 9), with 31.6% of 
peaks at promoters and the rest nearly equally divided between intergenic and intronic 
regions, with a small fraction annotated as exonic.
Differential peak accessibility
Reads aligning to the atlas peak regions were counted using htseq-count (-r pos s no). 
Differential accessibility of the peaks was assessed by applying DESeq2 v1.18.1 to this 
count table, considering all pairwise comparisons of cell types. Peaks were defined as 
differentially accessible if they satisfied an FDR-corrected P < 0.05 and if the magnitude of 
the DESeq-normalized counts changed by a stringent factor of 4 or more between at least 
one pairwise comparison of organoid line to control (the comparisons used were EV day 1 
vs. FE255 day 1, EV day 1 vs. R219 day 1, EV day 1 vs. WT day 1, EV day 5 vs. FE255 
day 5, EV day 5 vs. R219 day 5, EV day 5 vs WT day 5, WT day 1 vs. FE255 day 1, WT 
day 1 vs. R219 day 1, EV day 5 vs. FE255 day 5, WT day 5 vs. R219 day 5, sgNT day 5 vs. 
Adams et al. Page 13
Nature. Author manuscript; available in PMC 2019 December 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sgFOXA1-sg1 day5, and sgNT day5 vs sgFOXA1-sg2 day5) two-sided Wald test, with 
Benjamini-Hochberg correction for multiple observations. MA plots for pairwise differential 
accessibility analyses confirmed that normalization was appropriate and that differential 
peaks displayed robust changes (see Extended Data Fig. 10 for representative plots and 
Supplementary Table 16 for numbers of differentially accessible peaks). These analyses 
produced a set of ~20.5K differentially accessible peaks of median width 410bp; as 
expected, differential peaks were enriched for intergenic/intronic annotations and depleted 
for promoter annotations (Extended Data Fig. 9).
ATAC-seq peak clustering
The ATAC-seq peak heat maps were created using the DESeq size-factor normalized read 
counts, applying the variance-stabilizing transformation to the full peak atlas, selecting the 
differentially accessible peaks, and then clustering using hierarchical clustering with the 
ward.D distance metric. Clusters were defined by cutting the hierarchical clustering at the 
first 8 bifurcations of the dendrogram by ward.D distance. The number of clusters was 
chosen to be 8 based on observation of biologically interesting patterns of accessibility 
observation of biologically interesting differences in the clustering, and then peaks were 
sorted within each cluster by maximum signal
Peak heat maps
Heat maps (tornado plots) of peaks were generated by combining signals across replicates 
and binning the region +/− 750bp around the peak summit in 1bp bins after adjusting the 
reads for Tn5-induced bias, resulting in one signal track for each cell type/time point. Heat 
maps were generated using deeptools 3.0.2.
De novo transcription factor motif analysis
The Homer v4.10 utility findMotifsGenome.pl was used to identify the top ten transcription 
factor (TF) motifs enriched in each of the clusters produced by deeptools from each time 
point relative to genomic background. The top motifs were reported and compared to the 
Homer database of known motifs and then manually curated to restrict to TFs that are 
expressed based on RNA-seq data and to group similar motifs from TFs belonging to the 
same family.
FIMO motif search
Motif enrichment was performed relative to the 8 clustered defined by hierarchical clustering 
of 20,523 differentially accessible peaks (described above). Each ATAC-seq peak in the atlas 
was scanned for 718 TF motifs in the Mus musculus CIS-BP database40 using FIMO41 of 
MEME suite42, using the default P value cutoff of 1e-4. The background sequence 
distribution for motif analysis was based on nucleotide frequencies in the full set of 20,523 
differentially accessible peaks (A = T = 0.2711, C = G = 0.2289). Of the 718 motifs in the 
database, 713 had a match within at least one peak among the differentially accessible peaks.
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FIMO motif analysis
We restricted to 298 TFs whose median RNA-seq expression across biological replicates 
was above 5 RPKM in at lease one organoid line/time point. In addition, CTCF and CTCFL, 
DNA-binding proteins associated with 3D chromatin structure, were excluded. To rank the 
level of enrichment of TF motifs in each cluster relative to the background, the number of 
peaks containing each motif was calculated for each cluster and for the full set of 
differentially accessible peaks. Enrichment/depletion scores for each motif in a cluster were 
reported as binomial Z-scores relative to the background of motif occurrences in the set of 
differential ATAC-seq peaks. Namely, if p represents the probability that a peak in the 
background set contains an occurrence of the motif, then the binomial Z-score for a cluster 
of size N with C peaks containing the motif is C − NpNp(1 − p) . While these Z-scores do not 
incorporate a correction for multiple hypotheses, in practice the top-ranked motifs have such 
strong enrichments that they would still be highly significant after correction.
Non-canonical FOXA1 motif analysis
To examine enrichment/depletion of non-canonical Foxa1 motifs, we considered four 
additional motifs. First, we examined previously reported convergent and divergent Foxa1 
dimer motifs. Second, we altered the canonical Foxa1 motif by replacing position 6 of the 
core GTAAAC/T pattern with either and equal probability of C/T (similar to canonical) or an 
equal probability of A/G (non-canonical). We used FIMO to search for hits of these motifs 
across differential peaks and reported enrichment/depletion within clusters as binomial Z-
scores as before.
Chromatin Immuno-Precipitation (ChIP) coupled with Next Generation Sequencing (NGS)
Freshly sorted cells carrying pCW constructs (dsRED+) were seeded in duplicate per 
infected construct at the start of the assay, and moving forward, replicates were processed 
independently, collected following 5 days of doxycycline treatment. At time of collection, 
cells were trypsinized, and 70,000 cells (counted by using trypan blue exclusion) were 
processed for ChIP-sequencing as follows. Cells were fixed with formaldehyde (1%) and 
reaction was quenched with Glycine 1.25M and Tris 1M pH8. Fixed cells were lysed with 
SDS lysis solution containing protease inhibitors. Re-suspended pellets were sonicated, 
precipitated with antibodies (HNF-3 alpha/FoxA1 Antibody (3B3NB) (Novus Biologicals), 
AR (ER179(2), Abcam) and protein A/G bead complex. The chromatin and immune-
complex were sequentially washed with a low-salt solution, high-salt solution, LiCl solution 
and Tris-NaCl solution. Chromatin was eluted from the complex with a solution containing 
1% of SDS and 0.1 mol/l of NaHCO3. Cross-linking between DNA and protein was 
reversed by adding NaCl solution and incubating at 65°C over-night. Libraries were made 
using NEBNext Ultra II DNA library prep kit for Illumina (NEB E7645L). Quality control 
was performed with Bioanalyzer 2200 (Agilent technologies, D1000 screentapes & reagents, 
cat# 5067–5582) to assess size range of amplified DNA fragments, and with Quant-iT™ 
PicoGreen™ dsDNA Assay Kit (Thermofisher cat# P11496) to quantify the DNA fragments 
generated. ChIP Libraries were then pooled at equimolar concentration and were sequenced 
multiplexed on the Illumina HiSeq with 50bp paired-end sequencing.
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Bioinformatic analysis ChIP-seq
Raw reads were first trimmed with Trimmomatic 43 (v0.35, options: LEADING:3 
TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36) to remove adapters and low-quality 
sequences. They were then aligned with bowtie244 (v 2.2.6, options: --local --mm --no-
mixed --no-discordant) using mm10 genome. After alignment, PCR duplicates were 
removed with Picard tools (http://broadinstitute.github.io/picard/) (MarkDuplicates v2.9.0) 
and peaks were called individually for each replicate with MACS245 (v2.1.0.20151222, --
options: keep-dup 1 -g mm -p 0.05). These called peaks between replicates were then used 
with IDR46 (v2.0.2) framework to identify reproducible peaks. Deeptools (v3.1.3) was used 
for visualization and HOMER (v4.10.3) was used for discovering de novo motifs.
ChIP-seq normalization and analysis
To analyze ChIP-seq signal for AR and FOXA1 in each organoid line relative to ATAC-seq 
clusters, we normalized ChIP-seq data across experiments based on background signal, 
namely by defining flanking regions of reproducible peaks and using DEseq scaling factors 
relative to these regions for library size normalization. To compare AR or FOXA1 binding 
between a pair of organoid lines with respect to an ATAC-seq cluster, we compared the 
corresponding distributions of normalized ChIP-seq signal over peaks in the cluster by a 
one-sided Wilcoxon rank sum test.
Extended Data
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Extended Data Figure 1. Patients with predicted FOXA1 mutant status have worse outcomes.
(a) Co-crystal structure of the FKHD domain of FOXA3 in complex with DNA resembling 
the FKHD consensus sequence (PDB 1VTN), with residues and folds of interest indicated, 
including α-helix3 (orange), which sits in the major groove of DNA, and Wing2 (cyan), 
which undergoes frequent mutation in prostate cancer. (b) Kaplan-Meier showing 
significantly different clinical outcomes of time to biochemical recurrence (BCR, left) or 
progression to metastatic disease (MET,right) for predicted FOXA1 mutant cases vs. wild-
type in the GRID cohort. The difference of MET/BCR survival curves was tested via R 
survdiff function using G-rho family of tests, without adjustments for multiple comparisons. 
(c) Associations between predicted FOXA1 mutation status and clinical variables using 
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univariate analysis of the GRID cohort, with FOXA1 wild type as reference. The GRID 
cohort included 1,626 radical prostatectomy (RP) tumor samples. The center values 
represent the median odds ratio via univariate analysis. The error bars represent first and 
third quartiles of odds ratio. The lines represent minimum and maximum odd ratio. 
Univariate logistic regression analyses were performed on the GRID cohort to test the 
statistical association between FOXA1 mutant status and clinical variables via generalized 
linear test, without adjustments for multiple comparisons. The test was two-sided with the 
significance level of p <0.05 as the cutoff.
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Extended Data Figure 2. Details of FOXA1 luciferase reporter assay.
(a) Schematic of FOXA1 luciferase reporter, depicting the modified response elements (at 
wobble positions within the canonical FOXA1 motif) cloned in tandem upstream of a 
minimal promoter driving luciferase expression. (b) Dose response curve of FOXA1 
luciferase reporter activity in response to increased amounts of Foxa11WT cDNA introduced 
into the system, expressed as a relative response ratio with 100% Foxa1WT cDNA set to 1 
and 0% Foxa1WT cDNA (100% “stuffer” DNA) set to 0. Data from 3 biological replicates, 
central line and error bars represent mean +/− standard deviation. (c) Western blot of allelic 
series of FOXA1 mutants in HEK293T cells 24 hours after transfection with equal amounts 
of cDNA as used in FOXA1-luciferase reporter assay. CYCLO B = loading control 
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Cyclophilin B. Representative blot, experiment repeated 3 independent times with similar 
results. For source gel data, see Supplementary Figure 1.
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Extended Data Figure 3. Inducible overexpression of FOXA1 variants influences organoid lumen 
size and morphology.
(a) Schematic of dox-inducible pCW-FOXA1 constructs used in the study. (b) Western blot 
analysis of lysates from pCW-FOXA1WT organoids following acute dox treatment. 
Representative blot, experiment repeated 2 independent times with similar results. For 
source gel data, see Supplementary Figure 1. (c) Western blot analysis of lysates from 
organoids following long term dox treatment. Size of endogenous and FLAG-tagged 
FOXA1 noted, as well as the smaller truncated form from G275X at the expected size 
~38kDa. Representative blot, experiment repeated 3 independent times with similar results. 
For source gel data, see Supplementary Figure 1. (d) Quantification of lumen areas 
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measured at 10 days post-seeding. Solid black bar represents geometric mean, Values for 
sample size (indicated as dots) and p-values are as follows: EV (292), +WT (284, p<0.0001 
over EV), +R219S (60, <0.0001), +F254_E255del (119, <0.0001), +D226N (120, <0.0001), 
+R261C (114, <0.0001), +R219C (333, 0.2915), +G275X (75, <0.0001), +M253_N256del 
(150, 0.2006), +M253K (63, 0.2343), +Y259S (32, 0.2045), +Y259C (45, 0.0082), +F266L 
(107, 0.1219), +H247Q (63, 0.8343), +H247R (180, <0.0001), +H247Y (71, 0.9104). All p-
values are relative to WT unless noted, calculated using unpaired, two-tailed Student’s T-
test. Colors represent location of mutation within FOXA1. (e) Histology and IHC of 
organoid lines overexpressing additional alleles of FOXA1 (+WT or +Mut) via the 
doxycycline-inducible pCW vector 10 days after seeding. Images from a single biological 
experiment.
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Extended Data Figure 4. Analysis of FOXA1 alterations in FOXA1-deleted or PTEN-deleted 
contexts.
(a) CRISPR/Cas9 mediated knockdown of FOXA1 results in a significantly altered 
morphology. Organoids lacking FOXA1 (sgFOXA1) have a reduced capacity to form 
lumens while maintaining expression of AR and the basal marker p63 sgNT (guide RNA 
targeting human gene AAVS1) serves as a negative control. (b) Western blot analysis of 
lysates from organoids carrying control guide RNA (sgNT) or guide RNA targeting FOXA1. 
Representative blot, experiment repeated 3 times with similar results. For source gel data, 
see Supplementary Figure 1. (c) Quantification of organoids containing lumens, 7 days after 
trypsinization in normal organoid media. Data from 3 biological replicates, bars represent 
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mean +/− standard deviation, p-value calculated using unpaired, two-tailed Student’s T-test. 
(d) Sequence indicating the location of 3 silent point mutations introduced upstream of the 
PAM sequence for Foxa1 targeting RNA sgFoxa1_1. (e) Western blot analysis of lysates 
from organoids carrying either CRISPR-Zeo-sgGFP or sgFoxa1_1 in addition to the pCW 
construct indicated, either EV or with a FOXA1 allele present, plus or minus dox treatment 
for 10 days. Representative blot, experiment repeated 2 times with similar results. For source 
gel data, see Supplementary Figure 1. (f) Images of organoid lines carrying various 
combinations of guide RNA and cDNAs, 10 days after dox treatment. (g) Quantification of 
lumen containing organoids in lines with endogenous Foxa1 deleted via CRISPR/Cas9 
(sgFoxa1, sgNT as control guide) and overexpression of CRIPSR-resistant Foxa1 WT or 
mutant cDNA 10 days after seeding. Data from 2 biological replicates, bars represent mean. 
(h) Western blot analysis of lysates from PTEN-deficient organoids grafted into mice, with 
dox-induced overexpression of appropriate FOXA1 mutants. Representative blot, experiment 
repeated 2 times with similar results. For source gel data, see Supplementary Figure 1. (i) 
Overexpression of FOXA1WT or FOXA1G275X in sgPTEN organoids promotes tumor 
growth in mice at 6-weeks post engraftment into the flank of NOD-Scid Gamma mice. Data 
from the following number of tumors: EV=8, +WT=8, +R219S=10, +F254_E255del=10, 
+G275X=9, +ERG=10. Error bars represent mean +/− standard deviation, p-values 
calculated using unpaired, two-tailed Student’s T-test vs EV. Colors represent location of 
mutation within FOXA1. (j) Representative histology and immunohistochemistry (IHC) of a 
single tumor for given PTEN-deficient, FOXA1 expressing lines. Histology and IHC done 
on 5–9 tumors per line, from a single in vivo experiment, with similar results.
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Extended Data Figure 5. Analysis of the interplay between AR and FOXA1 in mouse organoids 
expressing FOXA1 variants.
(a) Box-plot representations of normalized counts from AR (left) and FOXA1 ChIP-seq 
(right) shown in Figure 3a to quantify the reduction in AR binding following FOXA1 wild-
type or mutant overexpression, and the increase in FOXA1 wild-type binding at those sites 
where AR is lost. Box: 25th to 75th percentile, band: median, top whisker: 75th percentile 
plus 1.5 times interquartile range, bottom whisker: 25th percentile minus 1.5 times 
interquartile range. Sample size = 2914 peaks. . p-values calculated using an unpaired, one-
sided Wilcoxon test. (b) Western blot analysis of lysates from AR-deficient organoids 
generated using CRISPR-Cas9 carrying representative FOXA1 alleles. Levels are 
Adams et al. Page 25
Nature. Author manuscript; available in PMC 2019 December 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
significantly reduced but AR is not completely absent (as seen on the long exposure) given 
that this is a bulk population rather than single cell clones thus a small number of cells 
escaped CRISPR/Cas9 mediated Ar deletion. Cells were treated with dox for at least 10 
days. Representative blot, experiment repeated 2 times with similar results. For source gel 
data, see Supplementary Figure 1. (c) Expression of mouse orthologs of AR target genes 
found in AR signature used in TCGA cohort analysis based on mouse organoid RNA-
sequencing analysis. Genes depicted are those that have a mouse ortholog of the human gene 
found in the signature, and a significant expression change (DESeq2 adjusted p-value < 
0.05) compared to EV control at 11 days +dox, as well as Psca, an AR target gene expressed 
in mouse organoids. Data from RNA-sequencing of 3 biological replicates. (d) 
FOXA1F254_E255del signature can predict mutant tumors in TCGA. Hierarchical clustering 
and heat map of significantly differentially expressed genes between mouse FOXA1F254_255 
organoids and EV control (FDR<=1×10−10). Human homologs of differentially expressed 
genes (DEGs) from this analysis were used to cluster FOXA1 mutant (n=14) and can detect 
nearly all FOXA1 mutant human tumors (p=2.1×10−8) out of the 333 TCGA samples, 199 
of which are ETS+. Two-sided Fisher-exact test was used to test the enrichment of FOXA1 
mutant samples within in sub-cluster, without adjustments for multiple comparisons.
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Extended Data Figure 6. Integrated analysis of ChIP-seq, ATAC-seq, and RNA-seq data in 
FOXA1 mutant organoid lines.
(a) Cluster 0 peaks have higher FOXA1 ChIP-seq signal in F254_E255del mutant organoid 
than empty vector control. Box plots show normalized day 5 AR ChIP-seq signal and 
FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 0, where 
normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly 
higher in F254_E255del and in WT compared to EV control (all P values can be found in 
Supplementary Table 11). Sample size = 5260 peaks. (b) Cluster 1 peaks have higher 
FOXA1 ChIP-seq signal and lower AR ChIP-seq signal in WT FOXA1 overexpressing 
organoid than empty vector control. Box plots show normalized day 5 AR ChIP-seq signal 
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and FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 1, where 
normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly 
higher, and AR ChIP signal significantly lower, in WT compared to EV control. Sample size 
= 1493 peaks. (c) Cluster 3 peaks have higher FOXA1 ChIP-seq signal in R219S organoid 
than empty vector control. Box plots show normalized day 5 AR ChIP-seq signal and 
FOXA1 ChIP-seq signal across different organoid lines at peaks from cluster 3, where 
normalization is based on background ChIP signal. FOXA1 ChIP signal is significantly 
higher in R219S compared to EV control. Sample size = 6641 peaks. (d) Cluster 5 peaks 
have higher FOXA1 ChIP-seq signal and lower AR ChIP-seq signal in R219S organoid than 
empty vector control. Box plots show normalized day 5 AR ChIP-seq signal and FOXA1 
ChIP-seq signal across different organoid lines at peaks from cluster 5, where normalization 
is based on background ChIP signal. FOXA1 ChIP signal is significantly higher, and AR 
ChIP signal significantly lower, in R219S compared to EV control. Sample size = 1983 
peaks. For panels a-d, box: 25th to 75th percentile, band: median, top whisker: 75th 
percentile plus 1.5 times interquartile range, bottom whisker: 25th percentile minus 1.5 
times interquartile range. p-values calculated using an unpaired, one-sided Wilcoxon test. (e) 
Genes associated with cluster 0 are significantly induced in F254_E255del mutant 
organoids. Top row: Plots show empirical cumulative distribution of log2 expression 
changes at 24hrs vs. day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant 
(right) organoids for all expressed genes (black), genes associated with at least one ATAC-
seq peak in cluster 0 (‘cluster 0-associated genes’, red), and the top quartile of these genes 
based on number of assigned cluster 0 peaks (‘strong cluster 0-associated genes’, yellow). 
Cluster 0-associated genes show strong expression induction compared to all genes in 
F254_E255del as well as in WT (red vs. black) but not in R219. Bottom row: As a control, 
similar cumulative log2 expression changes for cluster 1-associated genes (red) or strong 
cluster 1-associated genes (yellow) do not show significant induction in F254_E255del. All 
P-values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank sum tests. 
(f) Genes associated with cluster 0 are significantly induced in F254-E255del mutant 
organoids. Top row: Plots show empirical cumulative distribution of log2 expression 
changes at 11 days vs. day 0 in WT (left), F254_E255del mutant (middle) and R219S 
mutant (right) organoids for all expressed genes (black), genes associated with at least one 
ATAC-seq peak in cluster 0 (‘cluster 0-associated genes’, red), and the top quartile of these 
genes based on number of assigned cluster 0 peaks (‘strong cluster 0-associated genes’, 
yellow). Cluster 0-associated genes show strong expression induction compared to all genes 
in F254_E255del as well as in WT but not in R219. Bottom row: As a control, similar 
cumulative log2 expression changes for cluster 1-associated genes (red) or strong cluster 1-
associated genes (yellow) do not show significant induction in F254_E255del. All P-values 
are listed in Supplementary Table 12 and are one-sided Wilcoxon rank sum tests. (g) Genes 
associated with clusters 3 and 5 are significantly induced in R219S mutant organoid. Top 
row: Plots show empirical cumulative distribution of log2 expression changes at 24hrs vs. 
day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) organoids for 
all expressed genes (black), genes associated with at least one ATAC-seq peak in cluster 3 
(‘cluster 3-associated genes’, red), and the top quartile of these genes based on number of 
assigned cluster 0 peaks (‘strong cluster 3-associated genes’, yellow). Cluster 3-associated 
genes show strong expression induction compared to all genes in R219S but not in WT or 
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F255del. Bottom row: Similar analysis for cumulative log2 expression changes for cluster 5-
associated genes (red) and strong cluster 5-associated genes (yellow). These genes are 
significantly induced in R219S and repressed in F254_E255del in WT for this time point. 
All P-values are listed in Supplementary Table 12 and are one-sided Wilcoxon rank sum 
tests. (h) Genes associated with clusters 3 and 5 are significantly induced in R219S mutant 
organoid. Top row: Plots show empirical cumulative distribution of log2 expression changes 
at day 11 vs. day 0 in WT (left), F254_E255del mutant (middle) and R219S mutant (right) 
organoids for all expressed genes (black), genes associated with at least one ATAC-seq peak 
in cluster 3 (‘cluster 3-associated genes’, red), and the top quartile of these genes based on 
number of assigned cluster 0 peaks (‘strong cluster 3-associated genes’, yellow). Cluster 3-
associated genes show strong expression induction compared to all genes in R219S but not 
in WT or F255del. Bottom row: Similar analysis for cumulative log2 expression changes for 
cluster 5-associated genes (red) and strong cluster 5-associated genes (yellow). These genes 
are significantly induced in R219S and repressed in F254_E255del. All P-values are listed in 
Supplementary Table 12 and are one-sided Wilcoxon rank sum tests.
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Extended Data Figure 7. Motif analysis of ATAC-sequencing and modification of FOXA1 
reporter assay for evaluation of non-canonical FOXA1 motif.
(a) FIMO motif analysis of ATAC-seq clusters. Summary of motif enrichments/depletion 
results for each cluster relative to the background of all differentially accessible peaks, as 
reported by binomial Z-score. The top 15 enriched database motifs for expressed 
transcription factors are shown for each cluster. In addition, enrichment/depletion results for 
four additional FOXA1-related motifs are shown: convergent and divergent dimer motifs, 
and altered FOXA1 core binding motifs with either G/A or C/T at position 6. Transcription 
factors in parentheses represent motifs inferred from other species. Complete lists can be 
found in Supplementary Tables 3-10. (b) Top motif identified de novo using HOMER on 
ATAC-seq cluster 3 (R219S-specific) with motif core indicated, and variation from 
canonical FOXA1 motif depicted. p-values derived from one-sided binomial test. (c) 
Schematic of reporter design. Canonical response element reporter is same reporter used in 
Fig. 2, with various iterations of the canonical FOXA1 motif in tandem. Non-canonical 
motif has substitutions at position 6, indicated in pink, to reflect the newly identified motif 
enriched in cluster 3 of ATAC-seq. Note: the orientation of the upper motif cartoon and the 
sequence in the reporter schematic are the reverse complement of the motif identified by 
HOMER (GTAAAR). Modified base noted in position 6. (d) Dose response curve for both 
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FOXA1 luciferase reporters’ activity in response to increased amounts of Foxa1WT cDNA 
introduced into the system. Data shown is one representative biological replicate of 3 carried 
out, all showing same trends, but absolute luciferase/renilla ratios vary from experiment to 
experiment. (e) Results of reporter assays expressed as a relative response ratio, normalized 
to level of FOXA1WT activity for a given reporter. Data from 3 biological replicates, bars 
indicate mean +/− standard deviation. p-values derived using unpaired, two-tailed Student’s 
T-test.
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Extended Data Figure 8. Insert size distributions for ATAC-seq experiments and track figures 
demonstrating peak reproducibility across ATAC-seq replicates.
(a) Representative insert size distributions computed from individual ATAC-seq experiments 
based on aligned read pairs, showing modes corresponding to nucleosome-free regions, 
mono-nucleosomal fragments, and di-nucleosomal fragments. (b) Signal tracks for 
individual replicate ATAC-seq experiments at the Runx2, Plekha5, and Mbnl1 loci show 
reproducibility of accessibility events. DEseq scaling factors estimated from the atlas of 
IDR-reproducible peaks were used for library size normalization.
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Extended Data Figure 9. ATAC-seq peak annotation distributions.
Fraction of peaks annotated as promoter, intergenic, intronic, and exonic for full atlas of 
reproducible peaks, differentially accessible peaks, and by ATAC-seq cluster. See 
Supplementary Table 15 for full annotation counts.
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Extended Data Figure 10. MA plots for differential accessibility analysis.
(a) MA plots for differential accessibility analysis relative to EV controls. Representative 
MA plots (logFC vs mean read counts) for differential peak accessibility analysis of mutant 
and WT expressing organoid lines vs. empty vector controls at day 0, day 1, and day 5. 
Peaks that are significantly differential at FDR-corrected P < 0.05 are shown in color. Dotted 
lines at logFC = 2 and logFC = −2 show cut-offs used for requiring robust accessibility 
changes in pairwise comparisons. (b) MA plots for differential accessibility analysis at 
different time point relative to day 0. Representative MA plots (logFC vs mean read counts) 
for differential peak accessibility analysis in each organoid line at day 1 vs. day 0 and day 5 
vs. day 0. For a-b, all sample size n=183093 (number of peaks in the atlas). Peaks that are 
significantly differential at FDR-corrected P < 0.05 are shown in color, using two-sided 
Wald test with Benjamini-Hochberg correction.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Recurrent FOXA1 mutations in prostate cancer cluster in the FKHD DNA-binding 
domain
(a) Distribution of FOXA1 mutations from a pan-prostate cancer analysis of 3086 patients 
along linear protein sequence, depicting the various alterations seen in patients, and the 
amino acid sequence of the conserved FKHD DNA-binding domain, with secondary 
structural elements indicated. Residues in red are predicted to make contacts with DNA10. 
(b) Classification of FOXA1 alterations observed. Mutations can be subdivided into several 
classed based on their location within the FOXA1 protein. (c) Frequency of the various 
classes of FOXA1 alterations in the 3 clinical stages reported in MSK-IMPACT 504. All 
values are % of the total number of samples with FOXA1 mutations at a given clinical stage. 
(d) Prevalence of R219 mutations compared to all other point mutations found in FOXA1 in 
adenocarcinoma versus NEPC. Cases pooled from Trento/Cornell/Broad12 dataset and 
MSK-IMPACT 1708. ***p=0.0059, Fisher’s exact test, two-sided.
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Fig. 2. Expression of FOXA1 mutants promotes growth and reveals distinct morphologies for the 
various classes of alterations.
(a) FOXA1-luciferase reporter assay with results normalized to level of FOXA1WT activity. 
Colors indicate position of altered amino acid within the FKHD DNA-binding domain 
depicted in Fig. 1a. Grey indicates truncation. (b) Overexpression of FOXA1 promotes 
growth in prostate organoids in standard media conditions (solid lines, n=3) and in restrictive 
media conditions (dashed lines, no EGF, n=8). EV = pCW empty vector control. (c) 
Overexpression of wild-type (+WT) or various FOXA1 mutants promotes growth 10 days 
after seeding in media lacking EGF. (d) Quantification of lumen containing organoids for 
each line in the FOXA1 allelic series. All p-values are relative to EV, calculated using 
unpaired, two-tailed Student’s T-test. (e) Histology and IHC of organoid lines 
overexpressing various alleles of FOXA1 (+WT or +Mut) via the doxycycline-inducible 
pCW vector 10 days after seeding. Images from a single biological experiment. (f) Summary 
of GSEA comparing FOXA1 wild type or mutant organoid lines to EV control for a 
basal_low (luminal) gene set, the hallmark EMT gene set, and a gene set of the top 100 
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genes induced following ERF knockdown in organoids. Data from RNA-seq of 3 biological 
replicates for each organoid line. Only comparisons with an FDR of <0.25 are shown with 
the corresponding normalized enrichment score (NES). Gene sets with a positive NES are 
enriched in organoids carrying either FOXA1 wild-type or mutant alleles. For panels a-d, 
data represented as mean +/− standard deviation (SD). Values for n biological replicates 
(indicated as dots) as well as specific p-values can be found in the source data file. * 
indicates p<0.05, ** indicates p<0.01. All p-values are relative to +WT unless otherwise 
noted, calculated using unpaired, two-tailed Student’s T-test.
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Fig. 3. FOXA1 expression constricts the AR cistrome and promotes AR-independent growth 
programs.
(a) AR ChIP-sequencing in organoids overexpressing wild-type or mutant FOXA1 compared 
to control show significant changes in the AR cistrome in response to FOXA1 expression 
(left) and FOXA1 ChIP-seq showing FOXA1 binding at same loci. ChIP-seq data from two 
biological replicates. Statistical analysis of peaks can be found in Ext Data Fig. 6. (b) 
Overexpression of FOXA1 promotes growth in prostate organoids in the setting of 
significantly reduced AR (CRISPR-mediated deletion in a bulk population), in both standard 
media conditions (left panel) and in the absence of EGF (right panel). Two independent 
experiments result in the same growth trends for biological replicate 1 and 2.
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Fig. 4. FOXA1 mutations cause dramatic shifts in the chromatin landscape.
(a) Number of significant peaks open or closed (log2FC >2 for open, <−2 for closed peaks) 
after dox treatment for pCW-FOXA1wild-type or mutant organoids relative to EV. Right 
panel includes counts for FOXA1 CRISPR organoids 5 days after trypsinization relative to 
sgNT. Data from 3 biological replicates, with FDR <0.05 using two-sided Wald test, with 
Benjamini-Hochberg FDR correction for multiple observations. (b) ATAC-seq peak heat 
maps comparing organoids with (sgFOXA1_1, sgFOXA1_2) or without (sgNT) CRISPR 
deletion of Foxa1 or expression of WT or mutant FOXA1 after 5 days of dox treatment, with 
eight clusters defined by hierarchical clustering. (c) FOXA1 ChIP-seq signal at genomic loci 
matching ATAC-seq clusters defined in panel b shows a similar pattern of peaks correlating 
FOXA1 binding with open chromatin. Data from two biological replicates. (d) Enrichment 
or depletion of FOXA1 motif variants in clusters that gain accessibility in +F254_E255del or 
Adams et al. Page 42
Nature. Author manuscript; available in PMC 2019 December 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
+R219S organoids, including the canonical motif, divergent and convergent dimer motifs, 
and altered versions of the FOXA1 motif (GTAAAY, similar to canonical and GTAAAR, 
non-canonical), expressed as a binomial Z-score computed from the number of cluster peaks 
with >1 motif occurrence relative to background occurrence in all heatmap peaks. 
Occurrence within a given cluster is reported within the bar graph. Positive scores indicate 
enrichment; negative scores indicate depletion. (e) Luciferase reporter assay depicting 
activity of FOXA1 variants on GTAAAY (blue) or GTAAAR (red) DNA templates. 
Luciferase/Renilla signal normalized to signal from FOXA1WT on GTAAAY reporter. Data 
from 3 biological replicates represented as mean +/− standard deviation. p-values 
determined using unpaired, two-tailed Student’s T-test. No significant difference between 
activity of WT and R219S on the GTAAAR reporter (p= 0.2314). F254_E255del has 
significantly less activity on GTAAAR than either WT (p= 0.0059) or R219S (p= 0.0033).
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